120 Expression of lung resistance-related protein (LRP) in lung cancer

• Published in: European journal of cancer (1990) Vol. 31; pp. S28 - S29
• Main Authors: Dingemans, A.M.C., van Ark-Otte, J., van der Valk, P., Scheper, R.J., Postmus, P.E., Giaccone, G.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.11.1995
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(95)95375-G

Expression of LRP seems to be of prognostic relevance in advanced ovarian cancer and acute myeloid leukemia. In this study we evaluated the expression of LRP in lung tumor samples derived from patients and its relation to survival, tumor differentiation, TNM classification and histology. Immunohistochemical staining (IH) was performed on 42 frozen lung tumor tissue samples using the mouse monoclonal antibody LRP56 (IgG2b) directed to the 110 kD protein. LRP expression was calculated as the percentage of tumor cells which stained with the antibody. As cut-off point for Kaplan-Meier curves we took 10% LRP expression: comparisons of survival curves were performed by Mantel-Cox analysis. Kruskal-Wallis one-way nonparametric AOV was used to estimate whether the LRP expression was related to: tumor differentiation (well, moderately, poorly); TNM classification and histology. iH of the tumor sections showed different expression of LRP in the different histological subtypes of lung cancer (squamous cell carcinoma 83%; adenocarcinoma 59%; large cell/undifferentiated carcinoma 36% and SCLC 5%). LRP expression was significantly higher in squamous cell carcinoma than in the other subtypes (P < 0.05). Furthermore adenocarcinomas showed a significant (P < 0.05) higher LRP expression than the SCLC. No significant difference in expression levels was found between patients with different TNM-classification or tumor differentiation. In this relatively small group of patients, there was no relation between LRP expression and survival. Prospective research is being performed in patients undergoing chemotherapy.